trending Market Intelligence /marketintelligence/en/news-insights/trending/ZQxp3S_0MWVie-IAokqCqw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Theranos directors did not raise objections even as allegations mounted

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good

Street Talk Episode 67 - Veteran investor tabs Mick Mulvaney to help with latest financial stock-focused fund

Street Talk Episode 65 - Deferral practices trap US bank portfolios in purgatory

Report: Theranos directors did not raise objections even as allegations mounted

Theranos Inc.'s former board members George Shultz and Gary Roughead said they did not raise objections with CEO Elizabeth Holmes when allegations emerged that the company faked laboratory tests for its blood-testing technology, Bloomberg reported, citing court documents.

The former directors reportedly admitted in depositions that they did not think to raise the issue with the CEO as they believed her claims about the capabilities of the company's technology.

Roughead, a retired U.S. Navy Admiral, said he was aware that the company's executives sometimes used the technology of other companies for the analysis of blood samples but did not have knowledge of the extent to which this practice was used until news reports emerged.

Bloomberg reported that Tyler Shultz, a former Theranos employee, said Holmes exaggerated the capabilities of the technology to George Shultz, a former U.S. secretary of state, to gain a business advantage. He reportedly stated in a deposition that the company's claims such as the ability to run multiple blood tests from a single drop of blood and being able to run multiple tests simultaneously were false.

The depositions were reportedly made as part of an investor lawsuit. Theranos recently reached a settlement with the investor Partner Fund Management LP, which had sued the California-based company for allegedly misleading it into investing in the company.

Partner Fund reportedly believed Theranos used a shell company to secretly buy commercial-lab equipment and then pretended they were using the company's technology to run "fake 'demonstrations tests' for prospective investors and business partners."

Theranos also agreed in April to pay about $4.7 million to Arizona residents, who used its services between 2013 and 2016, in consumer restitution as part of a settlement reached with the Arizona attorney general.